related to Pharmacokinetics · 15Sirolimus → CYP2C8, CYP3A4, CYP3A5, Dose-corrected, Drug, However, In, It, P-glycoprotein, P-gp, PK, SRL, TAC, The, This
related to Legal status · 14Sirolimus → August, Committee, European Medicines Agency, European Union, GmbH, Human Use, Hyftor, In February, May, Medicinal Products, Plusultra, Rapamune, The, United States
has prevention · 11Sirolimus → FDA, However, Impaired, In, It, Its, October, The, Transplant, US, Wyeth
related to Pharmacodynamics · 9Sirolimus → Ciclosporin, Complex, FK-binding, FKBP12, IL-2, PP2B, Target Of Rapamycin, The, Unlike
has effect · 8Sirolimus → However, In, NIH, Novartis, The, This, Two, Ultimately
related to Lymphangioleiomyomatosis · 8Sirolimus → FDA, In May, LAM, Loss, Serious, The, This, TSC2
related to Angiofibromas · 7Sirolimus → English-language, Facial, FDA, In April, Reported, The, TSC
related to Cancer · 7Sirolimus → CCI-779, However, Kaposi's, Other, RAD001, The, When
related to Medical uses · 7Sirolimus → EU, Fyarro, Hyftor, In, PEComa, Rapamune, US
related to Tuberous sclerosis complex · 7Sirolimus → After, Novartis's RAD001, Numerous, TSC, United States, US, Wyeth's Rapamune
